122 related articles for article (PubMed ID: 37826938)
1. A physiologically-based pharmacokinetic model for predicting doxorubicin disposition in multiple tissue levels and quantitative toxicity assessment.
Chao FC; Manaia EB; Ponchel G; Hsieh CM
Biomed Pharmacother; 2023 Dec; 168():115636. PubMed ID: 37826938
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine.
Huang W; Czuba LC; Isoherranen N
J Pharmacol Exp Ther; 2020 Jun; 373(3):488-501. PubMed ID: 32198137
[TBL] [Abstract][Full Text] [Related]
3. A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human.
Montanha MC; Howarth A; Mohamed DA; Loier E; Main L; Rösslein M; Delmaar C; Prina-Mello A; Siccardi M
Drug Deliv Transl Res; 2022 Sep; 12(9):2178-2186. PubMed ID: 35551629
[TBL] [Abstract][Full Text] [Related]
4. Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically-based pharmacokinetic modeling.
Lee JB; Zhou S; Chiang M; Zang X; Kim TH; Kagan L
Biopharm Drug Dispos; 2020 Apr; 41(4-5):192-205. PubMed ID: 32342986
[TBL] [Abstract][Full Text] [Related]
5. A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition.
Dubbelboer IR; Lilienberg E; Sjögren E; Lennernäs H
Mol Pharm; 2017 Mar; 14(3):686-698. PubMed ID: 28182434
[TBL] [Abstract][Full Text] [Related]
6. Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.
Vaidya TR; Mody H; Franco YL; Brown A; Ait-Oudhia S
AAPS J; 2021 Jan; 23(1):18. PubMed ID: 33404976
[TBL] [Abstract][Full Text] [Related]
7. A Multiscale Physiologically-Based Pharmacokinetic Model for Doxorubicin to Explore its Mechanisms of Cytotoxicity and Cardiotoxicity in Human Physiological Contexts.
He H; Liu C; Wu Y; Zhang X; Fan J; Cao Y
Pharm Res; 2018 Jul; 35(9):174. PubMed ID: 29987398
[TBL] [Abstract][Full Text] [Related]
8. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
[TBL] [Abstract][Full Text] [Related]
9. Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition.
Emoto C; Johnson TN; Yamada T; Yamazaki H; Fukuda T
Eur J Clin Pharmacol; 2021 Aug; 77(8):1157-1168. PubMed ID: 33527208
[TBL] [Abstract][Full Text] [Related]
10. The effect of age on the early disposition of doxorubicin.
Li J; Gwilt PR
Cancer Chemother Pharmacol; 2003 May; 51(5):395-402. PubMed ID: 12679882
[TBL] [Abstract][Full Text] [Related]
11. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
12. A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.
Hu ZY; Lu J; Zhao Y
Br J Pharmacol; 2014 Jun; 171(11):2778-89. PubMed ID: 24471734
[TBL] [Abstract][Full Text] [Related]
13. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.
Hanke N; Teifel M; Moj D; Wojtyniak JG; Britz H; Aicher B; Sindermann H; Ammer N; Lehr T
Cancer Chemother Pharmacol; 2018 Feb; 81(2):291-304. PubMed ID: 29204687
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
Peters SA
Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
[TBL] [Abstract][Full Text] [Related]
15. Research tools for extrapolating the disposition and pharmacokinetics of nanomaterials from preclinical animals to humans.
Valic MS; Zheng G
Theranostics; 2019; 9(11):3365-3387. PubMed ID: 31244958
[TBL] [Abstract][Full Text] [Related]
16. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man.
Bradshaw-Pierce EL; Eckhardt SG; Gustafson DL
Clin Cancer Res; 2007 May; 13(9):2768-76. PubMed ID: 17473210
[TBL] [Abstract][Full Text] [Related]
17. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.
Li GF; Wang K; Chen R; Zhao HR; Yang J; Zheng QS
Acta Pharmacol Sin; 2012 Nov; 33(11):1359-71. PubMed ID: 23085739
[TBL] [Abstract][Full Text] [Related]
18. Model-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients.
Thiel C; Cordes H; Conde I; Castell JV; Blank LM; Kuepfer L
Arch Toxicol; 2017 Feb; 91(2):865-883. PubMed ID: 27161439
[TBL] [Abstract][Full Text] [Related]
19. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
Arora S; Pansari A; Kilford PJ; Jamei M; Turner DB; Gardner I
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):483-495. PubMed ID: 35486324
[TBL] [Abstract][Full Text] [Related]
20. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development.
Voisin EM; Ruthsatz M; Collins JM; Hoyle PC
Regul Toxicol Pharmacol; 1990 Oct; 12(2):107-16. PubMed ID: 2259752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
